Physician profile

Alison Smith

Family · Manchester, MD

NPI 1639894561

$480.52

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$480.52

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $246.17 2023-2024
Pfizer INC. $50.70 2023
Novo Nordisk INC $38.07 2023 Rybelsus, Ozempic
Lilly USA, LLC $31.61 2023 Emgality, Jardiance, Mounjaro
Indivior INC. $30.04 2024 Sublocade
Sumitomo Pharma America, INC. $28.48 2024 Gemtesa
Amgen INC. $20.38 2024 Otezla, Repatha
Dexcom, INC. $18.86 2023 Dexcom G6 Transmitter
Astrazeneca Pharmaceuticals Lp $16.21 2024 Breztri

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Alison Smith

$480.52

in general payments reported 2019-2025

Years
2023-2024
Top company
Abbvie INC.

https://glasscript.com/doctor/11409142/alison-smith

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.